WALTHAM, Mass. & MONTREAL–(BUSINESS WIRE)–Ventus Therapeutics, a clinical-stage biopharmaceutical company utilizing its proprietary, machine learning-enabled, computational chemistry platform, ReSOLVE, and its deep protein science expertise to develop differentiated small molecule therapeutics, today announced the opening of a new laboratory and office facility in Montreal, Canada. The new 24,000-square-foot state-of-the-art facility more than doubles Ventus’ laboratory and office space in Montreal and allows Ventus to strategically expand its R&D capacity to enable the continued growth of its pipeline and further development of its proprietary ReSOLVE™ platform.
“This new facility expands our presence in Montreal and augments our existing facilities in Waltham, MA,” said Marcelo Bigal, M.D., Ph.D., President and CEO of Ventus. “The Montreal expansion will provide us with an increased footprint that enables us to enhance our R&D efforts, including further building out our ReSOLVE™ platform. ReSOLVE™ has already enabled three clinical-stage compounds, including our first-in-clinic, orally administered cGAS inhibitor, an important target for multiple autoimmune disorders that has remained elusive to other drug discovery approaches. ReSOLVE™ is a powerful ML-enabled drug discovery engine that can be leveraged across multiple therapeutic areas to rapidly identify and develop novel small molecule drugs for undruggable targets.”
The new facility serves as Ventus’ Montreal-based offices and laboratories for its drug discovery and development organization, including its medicinal chemistry, computational chemistry, DMPK, and disease biology teams. This new facility represents the second phase of Ventus’ global expansion and augments Ventus’ 13,000-square-foot facility in Waltham, Massachusetts, which houses Ventus’ corporate offices and laboratories for its structural biology, biochemistry, protein sciences, molecular biology, and cellular biology teams.
“We have already validated ReSOLVE™ for many targets, including those deemed undruggable,” said Ventus Chief Scientific Officer, Michael Crackower, Ph.D. “Our new lab facility will be pivotal in advancing our vision to further develop ReSOLVE™ into a disruptive small-molecule platform that will revamp traditional drug discovery with unprecedented efficacy and speed.”
About Ventus Therapeutics
Ventus Therapeutics is a clinical-stage biopharmaceutical company deploying deep protein science expertise and a proprietary computational chemistry platform to develop novel small molecule therapeutics for immunology, inflammation, and neurology disorders. Using its proprietary drug discovery platform, ReSOLVE™, the company screened its first target in 2020, selected three development candidates in 2022, and advanced its two wholly-owned product candidates into the clinic in 2023: VENT-03, a potent, selective, oral cGAS inhibitor in Phase 1, and VENT-02, a potent, brain-penetrant, oral NLRP3 inhibitor that has completed Phase 1. In addition, Ventus has out-licensed VENT-01, a peripherally-restricted NLRP3 inhibitor, to Novo Nordisk A/S. These programs exemplify Ventus’ robust discovery capabilities and focus on differentiated programs for multi-indication immunology and neurology targets. For more information, please visit www.ventustx.com and engage with Ventus on LinkedIn.
